Kala Pharmaceuticals Announces New Drug Application for KPI-121 0.25% for Dry Eye Disease Has Been Accepted for Review by the US Food and Drug Administration - Associated Press https://t.co/G5hQhNBgVU

Kala Pharmaceuticals Announces New Drug Application for KPI-121 0.25% for Dry Eye Disease Has Been Accepted for Review by the US Food and Drug Administration - Associated Press https://t.co/G5hQhNBgVU

— IDRO (@IDROOhio) December 26, 2018

from Twitter https://twitter.com/IDROOhio

December 26, 2018 at 06:17AM